Creative Biolabs offers innovative in vivo phage display service for isolating vascular endothelium targeting peptides. This service is supported by our exclusive in vivo phage display technical platform. This unique platform engages the standardized in vivo biopanning protocols with a personalized approaching strategy, which is specifically designed to target diversify tissues and consequently fit customers' very unique research objectives.

Background

Vascular endothelium is an essential component of body for either physiological function or as therapeutic target. Vascular endothelium, as a type of epithelium, lines the interior surface of blood vessels, forming an interface between circulating blood in the lumen and the rest of the vessel wall. Vascular endothelial cells consist in the entire circulatory system, from the heart to the smallest capillaries, and play a crucial role in many physiological processes, including blood-tissue exchange, activation and migration of white blood cells, fibrinolysis, and coagulation. In diverse parts of the body, vascular endothelium is morphologically and functionally different. It is well accepted that vascular endothelium has obvious molecular heterogeneity that tissue- and organ-specific molecules expressed in various vascular endothelium are different. Moreover, relevant researches have shown that vascular endothelium may be involved in the process of certain tumors metastasize to healthy tissues. Thus, deeper investigation to target vascular endothelium, and achieve more efficient delivery to specific organs and tissues is obviously meaningful. In this way, great potential has been indicated to discover and develop unique tissue- or organ-specific molecules from vascular endothelium as therapeutic tools which may improve the efficacy of many promising therapeutics.

Vascular Endothelium Targeting In Vivo Phage Library Screening Platform

Creative Biolabs has applied a powerful platform to select specific peptides targeting vascular endothelium with in vivo phage display random peptide libraries. Following intravenous injection, this method is able to isolate large amount of peptide ligands which specifically home to endothelial cell receptors of diverse tissues, such as lung, skin and pancreas.This technology can be used to identify novel endothelial receptors expressed differentially in normal and pathological conditions, which extend the ‘functional map' of the vasculature and enhance deeper understanding of endothelial biology. Due to the ability of directly against specific vascular receptors, such selected peptides can be in vitro or in vivo used as therapeutic compounds targets or imaging agents for endothelial cells. In addition, the vessel-specific peptides may also play a role in clinical applications of diseases such as cancer and other conditions that exhibit distinct vascular characteristics.

Fig.1 Schematic selection for internalization.¹

Other optional in vivo phage display screening services:

• In Vivo Phage Display for Muscle Targeting
• In Vivo Phage Display for Atherosclerosis Targeting
• In Vivo Phage Display for Human Synovium Targeting
• In Vivo Phage Display for Tumor Targeting

FAQ

1. What is vascular endothelium-targeting in vivo phage display library screening?

   Vascular endothelium-targeting in vivo phage display library screening is a method used to discover peptides or proteins that specifically bind to endothelial cells lining the blood vessels. This technique employs bacteriophage libraries to identify binding agents that can interact directly with the vascular endothelium, aiding in the development of targeted therapies and diagnostics for vascular diseases.

2. Why target the vascular endothelium in medical research?

   Targeting the vascular endothelium is crucial because it plays a central role in many physiological processes and diseases, including atherosclerosis, thrombosis, inflammation, and angiogenesis. Precisely targeting the endothelium can improve therapeutic outcomes by directly modulating these processes, potentially offering treatments with higher efficacy and fewer side effects.

3. What are the primary applications of endothelium-targeting phage display?

   The applications include creating therapies that modulate vascular functions such as blood clotting and inflammation, developing angiogenesis inhibitors for cancer treatment, and enhancing targeted drug delivery systems. Additionally, it's used for creating diagnostic tools that can detect early signs of endothelial dysfunction or disease.

4. What types of molecules are typically identified in endothelium-targeting phage display?

   Typically, peptides or small proteins that bind to endothelial-specific markers, such as integrins, vascular endothelial growth factor receptors, or other surface molecules unique to the endothelial cells, are identified. These molecules can serve as carriers for targeted drug delivery or as therapeutic agents themselves.

5. How does endothelium-targeting phage display differ from other targeting methods?

   Endothelium-targeting phage display is specifically designed to identify ligands that can navigate the complex vascular environment and selectively bind to endothelial cells. This specificity is crucial in differentiating between healthy and diseased tissues, particularly in diseases where endothelial cells play a key role.

6. What challenges are faced in endothelium-targeting phage display screening?

   Challenges include the need to bypass the non-specific binding to other blood components, achieving penetration through the blood vessel wall when targeting diseased tissues, and the potential for rapid clearance from the bloodstream. Additionally, maintaining the stability and activity of the peptides in the circulatory system is a significant concern.

Resources

Use the resources in our library to help you understand your options and make critical decisions for your study.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.